TO PREDICT EFFICACY BY DETECTING CIRCULATING ENDOTHELIAL CELL SUBSETS AND BLOOD PERFUSION PARAMETERS CHANGES IN VIVO TUMOR IN THE PHASE II/III STUDY OF ANLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: